Celldex (CLDX) Reports Positive Phase 2 of CDX-011 on Various Breast Cancers
Tweet Send to a Friend
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
